Scorr-Insert
X

Find Approved Gastroenterology Drugs in Clinical Development

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Bismuth Subsalicylate

            Therapeutic Area: Gastroenterology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Arcadia Consumer Healthcare

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition March 20, 2020

            Details:

            Acquisition further strengthens Arcadia's consumer healthcare product portfolio.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Scopolamine Butyl Bromide

            Therapeutic Area: Gastroenterology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Sanofi

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration April 22, 2020

            Details:

            Cara Care has teamed up with the Consumer Healthcare Business Unit of Sanofi Germany to provide Sanofi’s Buscomint® bei Reizdarm drug with Cara Care’s digital companion app for digestive conditions.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ustekinumab

            Therapeutic Area: Gastroenterology

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 16, 2020

            Details:

            Scottish Medicines Consortium has accepted Janssen Pharmaceutical’s Stelara for use on the National Health Service Scotland to treat moderately to severely active ulcerative colitis (UC) in adults.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Naloxegol

            Therapeutic Area: Gastroenterology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: RedHill Biopharma

            Deal Size: $67.5 million Upfront Cash: $52.5 million

            Deal Type: Divestment April 02, 2020

            Details:

            In 2015, AstraZeneca entered into a co-commercialisation agreement with Daiichi Sankyo, Inc. for Movantik in the US, which has now been transferred to RedHill.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Eravacycline

            Therapeutic Area: Gastroenterology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: AcelRx Pharmaceuticals

            Deal Size: $26.9 million Upfront Cash: Undisclosed

            Deal Type: Acquisition March 16, 2020

            Details:

            Tetraphase and AcelRx entered into a co-promotion agreement to market and promote XERAVA™ for the treatment of complicated intra-abdominal infections and DSUVIA® for the treatment of acute pain.

            Massachusetts General Hospital

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Vedolizumab

            Therapeutic Area: Gastroenterology

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Royalty Pharma

            Deal Size: $94.0 million Upfront Cash: Undisclosed

            Deal Type: Acquisition March 05, 2020

            Details:

            Through transactions such as this, Royalty Pharma is furthering our goal of accelerating innovation and making the life sciences research and development ecosystem more efficient and productive.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Potassium Chloride API,Sodium Chloride,Ascorbic Acid

            Therapeutic Area: Gastroenterology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: FAES FARMA, S.A. ES 48940 Leioa

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement February 12, 2020

            Details:

            Norgine signed exclusive licence and distribution agreements with Faes Farma S.A., Pharmacare Limited T/A Aspen Pharmacare and Swixx Biopharma to provide worldwide exposure to PLENVU.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Mesalazine

            Therapeutic Area: Gastroenterology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Kyowa Hakko Kirin Co Ltd

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement February 03, 2020

            Details:

            Kyowa Kirin will finish its commercialization activity for ASACOL on March 31, 2020, and Zeria will obtain the full rights of the commercialization activities for ASACOL from April 1, 2020.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Fosnetupitant Chloride,Palonosetron

            Therapeutic Area: Gastroenterology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Helsinn Group

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 27, 2020

            Details:

            Berlin-Chemie AG has been granted exclusive rights to import, distribute, promote, market and sell AKYNZEO® and ONICIT® in Russia and CIS region to manage chemotherapy-induced nausea and vomiting.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Linaclotide

            Therapeutic Area: Gastroenterology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Teva Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement January 23, 2020

            Details:

            Pursuant to the terms of the settlement, Ironwood and Allergan will grant Teva a license to market its 145 mcg and 290 mcg generic version of LINZESS in U.S.

            PharmaCompass